Sellas’ cancer vaccine extends survival in blood cancer trial, company says
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
360° PERSPECTIVE
Verified viewpoints, counter-arguments & evidence
Related Stories
Why data interoperability is critical to the future of hospital care
6 hours ago
I switched from whey to Happy Cultures yeast protein powders: My 1-month experience with Dubai Kunafa chocolate and filter coffee flavours
9 hours ago
Doctor explains why asthma and COPD are not the same and why knowing the distinction matters
9 hours ago
From skipping sleep to everyday stress, here are small lifestyle choices that may show up on your face over time
10 hours ago
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].


Comment
0Upholding journalistic discourse. No registration required.
No comments yet. Share your perspective!